Related Experiment Video
Updated: Aug 25, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth
Fuad S Shihab1, William M Bennett, Hong Yi
1Division of Nephrology, University of Utah School of Medicine, Salt Lake City, Utah, USA. Faud.Shihab@hsc.utah.edu
Abstract:
Sirolimus (SRL) is not nephrotoxic, but it has been shown to increase transforming growth factor (TGF)-beta. We investigated the effect of combining mycophenolate mofetil (MMF) with SRL on renal structure and function and on TGF-beta1. Rats treated with vehicle (VH), MMF 10 mg/kg/d, SRL 0.3 mg/kg/d, or SRL+MMF were killed at 28 days. The physiologic and histologic changes and expression of TGF-beta1, plasminogen activator inhibitor-1, and extracellular matrix proteins were studied. Although SRL alone did not alter renal function and structure, it increased TGF-beta1 mRNA by 44% and protein by 48% (P <0.05 vs. VH). Treatment with MMF did not affect TGF-beta1. When combined with SRL, MMF decreased TGF-beta1 expression to VH levels. A similar trend was observed with plasminogen activator inhibitor-1 and extracellular matrix proteins. The long-term consequence of increased TGF-beta in SRL-treated kidneys remains unknown. However, because MMF can reverse this trend, SRL and MMF combination therapy may be protective.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy